It has been demystified that knockdown of miR-23 abates the growth of breast cancer in vivo and that miR-382 triggers breast cancer metastasis by activating Ras/ERK signaling pathways via targeting RAS-like estrogen-regulated growth inhibitor (RERG) [163,164] (Figure 1 and Table 3). The gene discussed is MAPK1; the disease is breast cancer.